Teva Plans To Launch Six Biosimilars By 2027

With US Approvals In Hand, Teva And Alvotech Take Aim At Adalimumab And Ustekinumab

 
• By Dave Wallace

As well as focusing on near-term US biosimilar launches like its Alvotech-partnered US adalimumab and ustekinumab rivals to Humira and Stelara, Teva has outlined plans to launch a total of six biosimilars by 2027, with plenty more in the firm’s pipeline.

Pencil drawing outline of number 2027
Teva has outlined plans for six biosimilar launches by 2027 • Source: Shutterstock

More from Biosimilars

More from Products